Psychedelic Drug Treatments

Psychedelic Drug Treatments: Assisting the Therapeutic Process provides information about current and quite viable investigation into reviving and progressing with neurological research that began in the middle of the 20th century and was brought to a halt when certain drugs were banned in the 1970s. Using a question/answer format, the book will introduce you to the way in which the chemical compounds known as psychedelics affect the brain, provide you with the definitions of key terms particular to the neurological and psychological vocabulary, describe the specific disorders that can realistically be helped or relieved through treatment with psychedelics, and offer information with regard to current research being conducted in the field. This text will discuss the history of the earlier research efforts and will examine the likelihood of a resurgence of interest in the successful development of methods and practices of clinical therapy assisted by psychedelic drugs. The purpose of this volume is to promote an understanding of the use of psychedelics as tools to assist therapy and to challenge the 40-year-old prejudices against research into the possible benefits of these drugs. Features: •Questions and answers about the history, research, and treatments related to psychedelic drugs •Makes a case for the re-evaluation of psychedelics — LSD, MDMA (‘ecstasy’), DMT, psilocybin, ayahuasca, peyote, ibogaine, and more — and their clinical potential for treating a range of conditions from post-traumatic stress disorder and depression to autism and cluster headaches. •Includes numerous in-text resources such as links to Web sites, videos, articles, blogs, etc. from NIH, FDA, YouTube, and university/clinical studies

The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.

First published in 1979, Psychedelic Drugs Reconsidered is regarded by many as the most comprehensive, accurate, and accessible analysis of psychedelic drugs for the general reader. It records the extensive history of scientific research on, and societal experience with, psychedelic drugs. The Lindesmith Center reprint edition features a new introduction by the authors on recent developments in psychedelic research, as well as a preface by Dr. Ethan Nadelmann, director of the Lindesmith center.

Psychedelic Psychotherapy contains valuable insiders' information for those using psychedelics for their own healing, and for practitioners who facilitate their sessions. Its focus is the nitty-gritty of healing trauma using MDMA, LSD, and psilocybin.

“Pollan keeps you turning the pages . . . cleareyed and assured.” —New York Times A #1 New York Times Bestseller, New York Times Book Review 10 Best Books of 2018, and New York Times Notable Book A brilliant and brave investigation into the medical and scientific revolution taking place around psychedelic drugs--and the spellbinding story of his own life-changing psychedelic experiences When Michael Pollan set out to research how LSD and psilocybin (the active ingredient in magic mushrooms) are being used to provide relief to people suffering from difficult-to-treat conditions such as depression, addiction and anxiety, he did not intend to write what is undoubtedly his most personal book. But upon discovering how these remarkable substances are improving the lives not only of the mentally ill but also of healthy people coming to grips with the challenges of everyday life, he decided to explore the landscape of the mind in the first person as well as the third. Thus began a singular adventure into various altered states of consciousness, along with a dive deep into both the latest brain science and the thriving underground community of psychedelic therapists. Pollan sifts the historical record to separate the truth about these mysterious drugs from the myths that have surrounded them since the 1960s, when a handful of psychedelic evangelists inadvertently catalyzed a powerful backlash against what was then a promising field of research. A unique and elegant blend of science, memoir, travel writing, history, and medicine, How to Change Your Mind is a triumph of participatory journalism. By turns dazzling and edifying, it is the gripping account of a journey to an exciting and unexpected new frontier in our understanding of the mind, the self, and our place in the world. The true subject of Pollan's "mental travelogue" is not just psychedelic drugs but also the eternal puzzle of human consciousness and how, in a world that offers us both suffering and joy, we can do our best to be fully present and find meaning in our lives.

In the early 1950s, the leading centre of the world for LSD research was Weyburn, Saskatchewan, where two psychiatrists sought to revolutionize the treatment of mental illness and, in the process, gave rise to a new form of therapy: psychedelic psychiatry. Psychedelic Psychiatry is the tale of medical researchers working to understand LSD’s therapeutic properties just as escalating anxieties about drug abuse in modern society laid the groundwork for the end of experimentation at the edge of psychopharmacology. Historian Erika Dyck deftly recasts our understanding of LSD to show it as an experimental substance, a medical treatment, and a tool for exploring psychotic perspectives. She recounts the inside story of the early days of LSD research in small-town, prairie Canada, when Humphry Osmond and Abram Hoffer claimed incredible advances in treating alcoholism, understanding schizophrenia and other psychoses, and achieving empathy with their patients. In relating the drug’s short, strange trip, Dyck explains how societal concerns about countercultural trends led to the criminalization of LSD and other so-called psychedelic drugs. In this well-written and fascinating book, she confronts the ethical dilemmas of the time and challenges the prevailing wisdom behind drug regulation and addiction therapy.

We are in the midst of what is being called the ‘psychedelic renaissance’ with growing interest into how psychedelics alter consciousness, brain function and brain connectivity. The acute, often profound, effects of the psychedelic experience can induce lasting improvements in mental health demonstrating that chemistry forms the basis of mystical experience, consciousness and mental wellbeing. This volume is a collection of chapters by world leaders in fields of neurobiology, neuropsychiatry, psychology, ethnography and pharmacology, addressing the neurobiological mechanisms of action of various classic and atypical psychedelics, their therapeutic potential as well as the possible risks associated with their use